Merck has completed its acquisition of Verona Pharma, making the company a wholly-owned subsidiary. As part of the deal, Verona Pharma's American Depositary Shares will no longer be listed or traded on the Nasdaq Global Market. This transaction brings Ohtuvayre (ensifentrine), a first-in-class maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, into Merck's cardio-pulmonary portfolio. Ohtuvayre, recently approved by the U.S. Food and Drug Administration, is the first novel inhaled mechanism for COPD maintenance in over 20 years and combines bronchodilator and non-steroidal anti-inflammatory effects. Merck plans to expand access to Ohtuvayre and will work with new colleagues from Verona Pharma to further build on the medicine's performance.